Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

References

• Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Therapy 2014; 16:R56; http://dx.doi.org/10.1186/ar4491
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Therapy 2009; 11 Suppl 1:S1; http://dx.doi.org/10.1186/ar2666
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492-509; PMID:24161836; http://dx.doi.org/10.1136/annrheumdis-2013-204573
   PubMed Web of Science ®Google Scholar
• Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Curr Pharmaceutical Design 2011; 17:3141-54; http://dx.doi.org/10.2174/138161211798157658
   PubMed Web of Science ®Google Scholar
• Villeneuve E, Haraoui B. To switch or to change class-the biologic dilemma in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6:301-5; PMID:20386564; http://dx.doi.org/10.1038/nrrheum.2010.45
   PubMed Web of Science ®Google Scholar
• Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 2014; 44:339-47; PMID:24310226; http://dx.doi.org/10.1002/eji.201344184
   PubMed Web of Science ®Google Scholar
• Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, van Lent PL, van de Loo FA, van den Berg WB. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011; 63:2329-39; PMID:21520013; http://dx.doi.org/10.1002/art.30418
   PubMed Web of Science ®Google Scholar
• Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71:1741-8; PMID:22550316; http://dx.doi.org/10.1136/annrheumdis-2011-201024
   PubMed Web of Science ®Google Scholar
• Grabulovski D, Kaspar M, Neri D. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 2007; 282:3196-204; PMID:17130124; http://dx.doi.org/10.1074/jbc.M609211200
   PubMed Web of Science ®Google Scholar
• Bertschinger J, Grabulovski D, Neri D. Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel 2007; 20:57-68; PMID:17242027; http://dx.doi.org/10.1093/protein/gzl055
   PubMed Web of Science ®Google Scholar
• Schlatter D, Brack S, Banner DW, Batey S, Benz J, Bertschinger J, Huber W, Joseph C, Rufer A, van der Klooster A, et al. Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs 2012; 4:497-508; PMID:22653218; http://dx.doi.org/10.4161/mabs.20452
   PubMed Web of Science ®Google Scholar
• Banner DW, Gsell B, Benz J, Bertschinger J, Burger D, Brack S, Cuppuleri S, Debulpaep M, Gast A, Grabulovski D, et al. Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr 2013; 69:1124-37; PMID:23695257; http://dx.doi.org/10.1107/S0907444913006574
   PubMed Web of Science ®Google Scholar
• Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Therapeutics 2014; 13:2030-9; http://dx.doi.org/10.1158/1535-7163.MCT-14-0046-T
   PubMed Web of Science ®Google Scholar
• Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem 2014; 289:14392-8; PMID:24692552; http://dx.doi.org/10.1074/jbc.M113.534578
   PubMed Web of Science ®Google Scholar
• Urech DM, Feige U, Ewert S, Schlosser V, Ottiger M, Polzer K, Schett G, Lichtlen P. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{α} single-chain Fv antibody (ESBA105) designed for local therapeutic use. Ann Rheum Dis 2010; 69:443-9; PMID:19293161; http://dx.doi.org/10.1136/ard.2008.105775
   PubMed Web of Science ®Google Scholar
• Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, Langham C, Barker W, Aziz A, Snow MJ, et al. Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 2009; 394:905-21; PMID:19835883; http://dx.doi.org/10.1016/j.jmb.2009.10.008
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{α} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38:600-5; PMID:20071453; http://dx.doi.org/10.1124/dmd.109.031310
   PubMed Web of Science ®Google Scholar
• Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, et al. Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody. Arthritis Rheumatol 2015; 67:51-62; PMID:25303306; http://dx.doi.org/10.1002/art.38896
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, Study G. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-9; PMID:15146410; http://dx.doi.org/10.1002/art.20221
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66:228-34; PMID:16935912; http://dx.doi.org/10.1136/ard.2006.055111
   PubMed Web of Science ®Google Scholar
• Thomaidis T, Worns MA, Galle PR, Mohler M, Schattenberg JM. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma - a report of 2 cases. Oncology Res Treatment 2014; 37:674-7; http://dx.doi.org/10.1159/000365597
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014; 16(1):57-66; PMID:25524800; http://dx.doi.org/10.1016/S1470-2045(14)71170-2
   PubMed Web of Science ®Google Scholar
• Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24:89-98; PMID:20199124; http://dx.doi.org/10.2165/11530960-000000000-00000
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
   PubMed Web of Science ®Google Scholar
• Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326:480-505; PMID:11036659; http://dx.doi.org/10.1016/S0076-6879(00)26071-0
   PubMed Web of Science ®Google Scholar